Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much. Thanks for joining today's conference. With me, I have our CFO Agneta Palmér who will present the financials in a moment, but let's get started. We can move directly over to page number two, please. And let's start by looking at some of the highlights and key takeaways from the second quarter of 2024. Net sales increased by 15.7% in the second quarter. The organic growth part of this was 8.9%. Order intake for Getinge increased by 14.4%, and the organic part here was 7.8%, thanks to positive development in all our three business areas. Adjusted gross margins improved in all business areas, and the adjusted EBIT margin for the group improved by 4.9 percentage points year-on-year. This is mainly coming from the weak comparison from last year, plus healthy growth mix and price, mitigating the negative effects from inflation that we still see. These are effects that we continuously address through productivity improvements and structural changes when and where needed. All in all, this contributes to a solid financial position that enables investments in profitable growth also going forward. We can then move over to page number three, please. So let's take a look at some of wkey activities that will drive future growth and profitability. In terms of our offerings and customers, I'd like to mention that in the quarter we launched the Poladus 150. It's an advanced low-temperature sterilizer that meets an important need for our customers. From a regulatory perspective, we received FDA 510(k) clearance for our Advanta V12 Clinical Guidance digital offering, which enables digital clinical decision support. And we also had an EU MDR approval for our coverage. Stent system advanced to V12. Within Life Science, the GW 888 Neo washer was launched, which contributes to increased efficiency in the clean room, and it also reduces water consumption by 20%. In addition to this, we had a new version of our DPT beta bag launched, and this version is made from a larger portion of renewable materials in the quarter as well. On May 15th, we had a capital market update presenting the updated adjusted earnings per share target of an average growth of over 12% in the years 2024 through 2028. When it comes to sustainability and quality, the quality improvement work linked to the Balloon Pump Cardio Save and the Access System Cardio Health. As previously communicated, we have actively promoted in the US these products, but we are still able voluntarily to sell and deliver if our customers see no good alternative. We are in close dialogue with customers and authorities, but it's too early to single out any specific trend in sales when it comes to this. In the quarter, we also submitted an application for CE marking of the new packaging for the ECMO therapy consumables, HLS and PLS sets. We can then move over to over to page number four please. So as I mentioned earlier, the order intake grew by 14.4% where of 7.8% organically and net sales increased by 15.7%, where of 8.9%. Organically and regionally oriented growth was strong in EMEA and Asia Pacific, and the decline in organic order intake in the Americas is mainly due to a softer quarter for Life Science and for surgical workflows. All regions grew net sales organically in the quarter, mainly driven by an improvement in acute care therapies compared with the challenging Q2 of last year. You can then move over to page five, please. So all of this combined takes us to the outlook, where we reiterate our previous guidance for 2024. We expect organic net sales growth to be 2 to 5%. And in addition to this, we expect recent acquisitions to contribute 3 to 5 percentage points of growth. And this is unchanged. We can move to page number six please. And we'll take a closer look at the order intake of the second quarter. So per business area in acute care therapies, we had 8% organic growth. This increase is mostly driven by critical care, cardiopulmonary, and cardiac surgery. Life science had an 18.4% organic growth. And, this was after a strong quarter in sterile transfer. The development in bioprocessing was still weak, as you've seen in the earlier quarters as well. In surgical workflows, the growth was 3.4% organically with an increase in all product categories except for digital health solutions. So in summary, for the group, this means 7.8% organic order intake growth and in actuals, 14.4%. You can then move to page number seven, please. And then from a sales perspective, a noticeable increase was seen. Organic net sales increased sharply following higher sales of consumables in both cardiopulmonary and cardiac assist compared to the difficult Q2 last year. And life science organic net sales decreased by 13.1% in the quarter, mainly due to washer, disinfectants, sterilizer and sterile transfer. However, sales from high purity processes in New England in the quarter make up for almost all of this. And when it comes to surgical workflows, organic net sales decreased slightly, mainly due to lower sales in infection control. The acquisition of Health Mark continues to contribute to growth in a material way; overall, for the group, acquisitions contributed an increase in net sales of 499 million in the quarter. Currency had a -5 million SEK impact on net sales for the group in the quarter. And when it comes to revenue from consumables, this was strong in the quarter, contributing to high growth in recurring revenue. Let's move over to page number eight. And if we take a closer look at the gross margin and gross profit, gross profit increased by 837,000,006 to 4,151,000,006 in the quarter, where foreign exchange effects impacted by plus 35 million SEK. All business areas improved their adjusted gross margin, leading to a 3.8 percentage point increase for the group relative to last year's lower comparatives. A mix of price absorption and FX had a positive impact, while cost inflation still erodes the margin, and this is something we continue to address. For acute care therapies, the adjusted gross margin improved by 3.6 percentage points, mainly due to increased sales, the product mix inside the business area, and currency. This was partly offset by higher costs for input goods, employees, and ongoing quality improvement efforts with regard to cardiac assist and cardiopulmonary. For life science, the adjusted gross margin increased by 2.8 percentage points due to a favorable mix, price improvements, and currency. And this was partly offset by lower volumes and low absorption in surgical workflows. The adjusted gross margin increased by 2.8 percentage points, mainly as a result of acquisitions and price increases. And with that, we'll move over to page number nine. And I hand over to you.
Okay. Thank you, Mattias. Let's have a look at adjusted EBITDA, which improved by 486 million Swedish kronor, and the margin came in 4.9 percentage points higher than last year. Adjusted gross profit had a positive effect on the margin by 3.3 percentage points, due to those factors that were just mentioned: materials volume mix, favorable price absorption partly offset by inflationary effects. Opex, adjusted for currency, had a positive impact of one percentage point on the margin in the quarter, coming from operating leverage and positive contributions from acquisitions, depreciation, and amortization. Adjusted currency had a positive effect of 0.5 percentage points on the margin, and finally, FX had a slightly positive impact on the margin. So all in all, this resulted in an adjusted EBITDA of 981 million Swedish kronor and a margin of 11.8%. Over to page ten, please. Free cash flow amounted to 0.3 billion, roughly. A higher operating profit had a positive effect while higher level of working capital impacted negatively, and the higher working capital is to a large extent related to seasonally higher levels of receivables and inventory. Even so, working capital days continue to be well below 100. We are now at 91.6 days. We remain below trend on operating return on invested capital, with 11.1% on a rolling 12 month basis, which is still above the cost of capital. Let's move to page 11. The change in net debt year over year is due to the acquisitions that were finalized in the fourth quarter of 2023, taking us to $9 billion in net debt at the end of this quarter. If we adjust for pension liabilities, we are at 6.3 billion. This brings us to a leverage of 1.5 times EBITDA. If we adjust for pension liabilities again, the leverage is at 1.1 times. Cash amounted to approximately 2.3 billion. At the end of the quarter. So all in all, we can conclude that the financial position continues to be strong. Let's then move to page 13, please. And back to you, Mattias.
Okay.
Thanks. Let me just briefly summarize Q2. We continue to grow orders and net sales, and we've also launched a large number of value-adding products in the quarter, which I think is particularly encouraging. We reiterate our guidance for the full year, 2 to 5% organic net sales growth. And in addition, we expect the recent acquisitions to contribute with 3 to 5 percentage points of growth. The adjusted EBIT stage margin came in 4.9 percentage points higher than last year, thanks to a healthy growth mix and price. Mitigating the negative effects of inflation, which we continue to address through productivity improvements and structural changes as needed. All in all, this contributes to a solid financial position that enables continued investments in profitable growth for Getinge. The current priorities for us are really about addressing remaining quality-related challenges in acute care therapies. It is to work with sustainable productivity improvements and to continue creating added value for our customers. So with that summary, I open up for questions so we can move to the Q&A part of this call please.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Eric Castle from Danske Bank. Please go ahead.
Hi. Good morning and congrats on the good results. First, I'd like to ask about the short-term trends you're seeing in customer loss within balloon pumps. If a transition happens, my indication is that customers make that decision relatively fast. I mean, if you see a real risk, you act on it, basically. That's the way it's been. But why? Why should it be different for you? Why can't you really say anything about that now?
Yes, thanks, Eric. I mean, it's definitely one theory. It's just difficult to predict; some customers we expect will take a little bit longer to evaluate why they should change, if they should change at all. So we're just humble about that. Really, but I assure you have a point, but I think it is a bit too early to predict. And we don't see any customer loss effects in either of the product categories at the moment.
Okay, thank you, thank you. And then I just wanted to ask how much of a stocking and pull forward effect do you think there is in EMO and balloon pumps right now in this quarter?
We can't really measure that. And I don't see why there should be a pull forward or stocking effect at all. Actually.
All right. Perfect. Thank you. Then lastly, you talk about strength in critical care in order intake. Are you seeing some sort of trend shifts or market share gain post the Philips exit in the US?
It's too early to say. We, like we said before, think this is going to be favorable for us. However, the strength right now, it's a little bit too early to ascertain. It's just one data point. So, I would wait a quarter or two before making any conclusions about this.
All right. Thank you very much. I'll jump back in, okay?
Thank you.
The next question comes from Richard Ander Kranz from Handelsbanken. Please go ahead.
Good morning, and thank you for taking my questions. At the Capital Markets Update in May, you mentioned having cleared 90% of the FDA's quality record backlog. Where are you now with that? And do you think you can complete the remaining issues or outstanding tasks before the year's end? That's the first question. Thank you.
Yes, we have made continued progress. We are now closer to around 95% completion, I'd say. And we are confident that we will have worked this through before the end of the year.
Very clear, thank you. I also noticed that there seems to be a bit of a step-up in extraordinary quality costs in the quarter. I guess it's somewhere around 200 million compared to 100 plus million in Q1. So, how should we think about H2, and how confident do you feel about the visibility of these costs and any swing factors we should consider?
Firstly, you correctly noticed that this is a step-up in the second quarter, but we expect in the second half of the year to normalize or return to quarter-one levels. So roughly 200 million in this quarter and then about a hundred million per quarter for the rest of the year, coming in at roughly half a billion for the full year.
Very clear. Thank abuse navigate for taking my questions. I'll stop there and get back in the queue.
The next question comes from Mathias Waddesdon from SEB. Please go ahead.
Yes. Hi. My first question would be if you could share a few more details on a tractor. I mean, growing orders by 17% organically, which is quite strong in all segments. So maybe a few general words and maybe also what is happening around Getinge in China. Please. That's the first one.
Yeah, yeah. Thanks for the question. I think we've had some good traction when it comes to surgical workflows on larger projects in Asia Pacific. I think that's the only thing I really want to single out. There's nothing else that stands out. We are overall positive about the market opportunities in Asia Pacific going forward, including China. I think if you look at the demand for healthcare, it is expected to continue to be strong. And we have generally good market positions in China as well. But there's nothing in the quarter that would single out particularly here.
Okay. Good. And more or less business as usual in that region in China. That's it.
Uh, yeah. It depends on what you mean by business as usual. But yes, I guess that's a way of expressing it.
Okay, good. And then I think there's quite a strong contribution from acquisitions as it looks, at least here in the quarter, and especially movements that we should be aware of here, or if it's just good performance. And then if you could comment on the margin profile for both acquired companies as well in this quarter.
Yeah, I think it's great to see the contribution from both health market and from high purity in New England. So strong growth from both of them and trading a little better than we expected when we acquired them. But again, nothing I mean they are strong companies. I mean Health Walk is obviously a much more mature, more established company with many more customers. IP in New England is reliant on fewer customers, but doing really well with those right now. So overall, good solid development since we acquired them last year. So it's more or less three quarters under our belt now and encouraging performance thus far.
Okay, and then the last one for me. Uh, for full-year margin expectations, I think you stand at some 12.7% here, the rolling 12. If you could share any thoughts on where you are set to expand margins in the second half, to move this up a little bit further for the full year. That's my last one. Thanks.
Thanks.
So we don't give guidance on the margin for the full year. Um, we have activities to address the cost base. That is what we, uh, what we can share. And we are, as you know, very exposed to the product mix that we see, which is in the second quarter, highly positive, but that is a different structural profile in the second half of the year as you are well aware. That is how we can comment on the margin.
Okay. Thank you very much.
Thank you.
The next question comes from Oliver Weinberg from Kepler. Curious. Please go ahead.
Oh, yeah. Good morning. Thanks for taking my question. Um, I mean, I want to come back to the first question on the strong performance in Act. And obviously, you called out the large contribution from echo in order to assist. So I'm just wondering, is there any kind of color in terms of, uh, any kind of unusual support in there? I mean, you talked about that. There's no pull forward effect in theory. I guess one can imagine that some clients order quickly before there's any kind of potential restrictions from their legal departments. So can you just talk about that fact? And also, has there been a major improvement in the order backlog that you had, for example? Question number one, please.
Yeah. No. As I said on the first question here, I think that is one theory, but it's not something that we are aware of. I think the only thing that has changed is that we have, uh, we've had a, uh, difficulty in supplying parts of the offering for cardiopulmonary, and we've been able to, uh, improve the capacity and the supply situation there. So that's a that's a positive. And I think we will be able to sustainably serve our customers better with this. But whether there is a pull forward effect, uh, because customers expect some restrictions going forward. We have no evidence of that at all. I mean, if we saw that, we would, uh, we would inform about it, but we don't see that right now.
Okay. And I guess on cardio, is this the kind of order backlog in the Q1 call you talked about that this is the kind of couple of months, uh, can you just give any kind of color how significant this order backlog still is for some space?
Yeah, we have still, uh, quite a number of balloon pumps that are waiting to be shipped. Uh, we have a small decrease, uh, month by month, quarter by quarter, but, uh, but still quite a few pumps to to ship, uh, but no material change, I think. Small steps in the right direction, but no material change from previous quarters.
Okay. Thank you. And the second question would just be on the orders in Act, which actually look quite strong. I think you had 18% growth in the second quarter. 12% in the first half. I guess there was obviously some kind of support from underlying commerce. But, um, also that you still have the kind of CE mark issue for categories. Can you just provide any kind of color on what was driving these orders in Europe and in fact, please.
Yeah, we can see that. What you mentioned, we had, of course, an effect last year also on the order intake in quarter two, where we had different, um, limitations to our ability to, uh, to deliver. So that impacted. We also have now with the distribution agreement that we have for stents, we have a slightly different ordering pattern, um, bulk orders rather than the, um, recurring orders for that product type. But overall, we see good, uh, activity, uh, with our customers in the market. And that is what we also see in the order intake.
Okay, perfect. And the last question for me, just in lifesciences, um, I think you talked about a better demand in terms of orders with the still transfer. I mean, do you see this as a kind of turning point, and any additional color you can provide on bioprocess, please?
Yeah. I think when it comes to sterile transfer, it's encouraging to see the, uh, better, uh, book to build ratio now. So hopefully this is now, uh, very near the end of the, of the destocking that's been going on for quite some, some time. Again, we're humble about, uh, this being, uh, one data point. Uh, but I think it looks more promising. We have from our biggest existing customers better order intake and also from our new customers for our transfers. We have also seen strengthening order intake. So, a good step in the right direction here for sure. And in bioprocessing, it's uh, it's and it seems to uh, in most parts of the world have bottomed out, while China still is, is difficult for us.
Okay. Thanks so much. Indeed.
Thank you.
The next question comes from Christopher. Algebra from Carnegie. Please go ahead.
Yeah, thank you. Three questions. First, a comment back to the previous one on Life Science. Now you have had four consecutive quarters without growth. When do you expect this business segment to start growing again? And then I just wonder about.
Uh.
New packaging approval.
For, for example, in Europe or CE regions. The timing for that. If you have any dialogue around that, I wonder about the time you had the capital markets update. Earlier this spring, you mentioned a more flattish mode in development. I think we'll see that in 2025. At the same time, we have seen a positive start to the year. I think you said the quality issue impact on earnings is 500 million, down from 800 million last year. And you say that you still see new impact on customer behavior because of the FDA regulations. So, is that comment still relevant, especially more so this year versus last year? Thank you.
Well, if we start with the life science growth, then it is, I think, encouraging to see the order intake continue to be strong here. Sales are weaker now because we have deliveries dictated by customers, more weighted towards the second half of this year. So what we do expect is the situation when it comes to sales to gradually improve also for life science. But one should keep in mind that these are large projects with rather long sales cycles. Our deliveries also depend on other suppliers and the overall projects that the customers are running. So we're sometimes at the mercy of other people's plans in this part of the business when it comes to the newer packaging. We have submitted applications for both HLS and PLS. We have a good dialogue with the notified body on this, but it's not in our hands to decide when this decision will happen. It's a constructive dialogue, but I can't predict any date for reinstating the CE marks. When it comes to the capital markets update guidance, I'll just refer to what Agneta Palmér said earlier, that we don't guide on this. It looks a bit more positive after this quarter, but it's too early to say. And we remain humble when it comes to the potential impact of the FDA letter to healthcare providers during the second half of the year. One theory, as some of you here in the call have stated, is that we should see a quick effect of this, which may or may not be true. So, we will just need to continue to evaluate this. We've factored in our base scenario, so to speak, in the guidance that we have for growth, as we stated at the capital markets updates. I really cannot provide any additional details today on this matter.
Thank you. So, what do you expect from this business to grow again in the second half of the year?
I didn't say exactly that. I said that we expect the best momentum sales-wise because our deliveries are more weighted now or phased into the second half of the year. But we don't give individual BA guidance here. So, Life Science sales are factored into the 2 to 5% growth that we have for the group.
Okay.
That's fair. Thank it very much.
Thank you.
The next question comes from David Adlington from J.P. Morgan. Please go ahead.
Good morning everybody.
Good morning.
Morning everybody. I just wanted to focus again on Act. So I mean the growth you've posted this quarter is the third best ever for Act, I think in your history, only beaten by Q3 and Q4 in 2020, where you had some fairly obvious tailwinds from Covid. I suppose, really, I'm trying to understand why, in a normalized environment, this has been your best ever growth quarter in Act. It's not really, uh, very clear to me what's been the real growth driver here. And then secondly, uh, I just wondered why you didn't highlight that Q2 is going to be so strong given the fact you had the capital markets event. You know, halfway through the quarter, there was no indication that Q2 was going to be so strong. I just wondered if anything changed post the Capital Markets Day. Thank thank you.
Yeah. When it comes to Act, I mean, the largest explanatory factor is obviously the weak performance from Q2 last year where we had a lot of challenges in both cardiopulmonary and cardiac assist. So there's a comp difference effect here that is significant. Uh, combined with this, we have, like I said, on one of the earlier questions, been able to improve supply. Uh, we've had many customers on allocation for a long time when it comes to our chemotherapy products. So that is a positive change as well, which is sometimes difficult to predict the timing of. So that's kind of the biggest explanatory factor. Then we have strong performance when it comes to critical care as well. And it remains to be seen whether this is an effect that we can count on. Also, going forward. I think it's a little bit too early to pass verdict on that.
Can I come back on a couple of things? Firstly, the company was only down 5% last year. So yes, it's easy, but that doesn't really explain more than 20% growth this quarter in itself. Uh, and then secondly, just with respect to that comment around, you know, why not highlight that Q2 is going to be a strong quarter and the capital markets event.
But we never intended to talk about individual quarters during the capital markets update. And even if it's a strong quarter relative to last year, we don't see this as a particularly strong quarter. This is not a performance that we're happy with. I think that's important to underline.
Okay. Thanks.
Thank you, David.
There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
All right. Thank you very it much. I think we've already summarized the second quarter of 2024, and I appreciate everyone taking the time to listen in today. So I think that will close, and I wish you a good rest of the day. Thank you very much.
Thanks, everyone.



















